Thelansis

 Multiple myeloma (MM) is a challenging hematological malignancy characterized by the uncontrollable growth of clonal plasma cells in the bone marrow. These cells produce significant quantities of immunoglobulins and other non-functional proteins. Despite numerous decades of progress and groundbreaking therapeutic advancements, MM remains largely incurable. These highly proliferative, differentiated B-lymphocytes can secrete a range of immunoglobulins (Ig), with IgG and IgA being the most common and IgD to a lesser extent. Typically, the abnormal plasma cells primarily reside in the bone marrow, and only a small minority of patients exhibit extramedullary disease at diagnosis. Most patients experience relapses during treatment, progressing to a refractory state, where they no longer respond to treatment within approximately 60 days after their last therapy. A bleak prognosis and a heightened risk of relapse characterize this. With each successive relapse, the progression-free survi...